Efficacy of Dexmedetomidine for endotracheal tube tolerance, analgesia and sedation – A prospective randomised double blind controlled trial

Peer review under responsibility of Egyptian Society of Anesthesiologists.

Figures & data

igure 1 CONSORT statement flow diagram – study design.

able 1 Patient demographics and baseline cardiorespiratory parameters of Group D (Dexmedetomidine) and Group P (Control).

	Group D	Group P	p
Weight	61.7 ± 13.2	58.1 ± 11.4	0.194
Baseline pulse rate	83.3 ± 12.2	84.7 ± 14	0.844
Baseline SBP	124.5 ± 10.9	130.4 ± 17.1	0.232
Baseline DBP	76.9 ± 7.4	79.3 ± 8.4	0.420
Mean BP	92.7 ± 7.2	96.4 ± 10.4	0.025
Baseline SpO2	98.7 ± 1.2	98.9 ± 0.8	0.606
Baseline respiratory rate	14.9 ± 1.3	14.7 ± 1.3	0.606
Duration of procedure	4 ± 1.3	3.6 ± 1.2	0.376
AGE	46.3 ± 13.3	49.8 ± 15	0.067
Male: Female	62.5: 37.5	56.3: 43.8	0.611
ASA Grade I: II	18.8: 81.3	18.8: 81.3	1.000

igure 2 Comparison of heart rate in Group D (Dexmedetomidine) and Group P (Control) in the ICU.

igure 3 Comparison of systolic BP and diastolic BP in Group D (Dexmedetomidine) and Group P (Control) in the ICU.

igure 4 Comparison of morphine requirement in Group D (Dexmedetomidine) and Group P (Control) in the ICU.

igure 5 Comparison of the percentage of patients in Group D (Dexmedetomidine) and Group P (Control) experiencing cough at different time interval in the ICU.

igure 6 Comparison of the quality of endotracheal tube tolerance in Group D (Dexmedetomidine) and Group P (Control) in the ICU. Mean value 1–2 (Excellent–Good), 2–3 (Good–Moderate).